HYPERSENSITIVE ESTROGEN RECEPTOR IN PREMALIGNANT BREAST

$250,646R01FY2000CANIH

Baylor College Of Medicine, Houston TX

Investigators

Linked publications & trials

Paper 38781103 Paper 38231165 Paper 37906431 Paper 34621045 Paper 34226682 Paper 33323970 Paper 33257837 Paper 31318440 Paper 30903140 Paper 29748621 Paper 29736566 Paper 29110152 Paper 28881599 Paper 27532824 Paper 27178332 Paper 26700205 Paper 26568765 Paper 26487496 Paper 25820519 Paper 25394532 Paper 25178514 Paper 24487689 Paper 24077732 Paper 23322423 Paper 23053665 Paper 22907432 Paper 22697792 Paper 22622808 Paper 22355776 Paper 22282662 Paper 22006997 Paper 21878538 Paper 21792626 Paper 21737614 Paper 21499302 Paper 21447808 Paper 21123450 Paper 20427689 Paper 20304996 Paper 20101208 Paper 19887647 Paper 19842032 Paper 19749156 Paper 19644018 Paper 19561644 Paper 19533338 Paper 19487288 Paper 19205871 Paper 19147702 Paper 17993238 Paper 17545528 Paper 17172405 Paper 16740736 Paper 16645043 Paper 15102680 Paper 14973381 Paper 12750263 Paper 12013530 Paper 11971970 Paper 11916222 Paper 11350726 Paper 11279135 Paper 10945602

Abstract

DESCRIPTION (Adapted from the Investigator's Abstract): The investigators hypothesize that appearance of a "hyper-sensitive" ER variant might be one of the earliest genetic events in breast cancer evolution, and as such might be an early biomarker useful for the early detection and ultimate prevention of breast cancer. This hypothesis will be tested via three Specific Aims: (1) To study the function of the hyper-sensitive ER variant using estrogen-responsive mammalian expression vector systems; (2) To determine whether expression of the hyper-sensitive ER variant is associated with early breast disease and with breast cancer evolution and progression in breast specimens from several clinical studies;. (3) To determine whether the hyper-sensitive ER variant acts as a promoter or facilitator of mammary carcinogenesis in transgenic mouse models.

View original record on NIH RePORTER →